Recent Finacing
Recent Raise
PrognomiQ develops multi-omics liquid biopsy tests combining proteomics, genomics, metabolomics, epigenomics and cell-free nucleic acids to detect and monitor cancers, pursuing CLIA LDT-to-IVD regulatory pathways.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at PrognomiQ.
